A Phase I/IIa Safety Study of Subretinal Implantation of CPCB-RPE1 (Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells Seeded on a Polymeric Substrate) in Subjects With Advanced, Dry Age-Related Macular Degeneration (AMD)

Trial Profile

A Phase I/IIa Safety Study of Subretinal Implantation of CPCB-RPE1 (Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells Seeded on a Polymeric Substrate) in Subjects With Advanced, Dry Age-Related Macular Degeneration (AMD)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 17 Apr 2017

At a glance

  • Drugs CPCB-RPE1 (Primary)
  • Indications Dry macular degeneration
  • Focus Adverse reactions
  • Sponsors Regenerative Patch Technologies
  • Most Recent Events

    • 17 Apr 2017 New trial record
    • 07 Apr 2017 This trial received funding from CIRM (California Institute for Regenerative Medicine), as reported in a Santen Pharmaceutical media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top